Get the Stockscreener App
154.38
1.09%
1.665
Belite Bio Inc Adr stock is traded at $154.38, with a volume of 78,873.
It is up +1.09% in the last 24 hours and down -8.89% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$152.72
Open:
$153.87
24h Volume:
78,873
Relative Volume:
0.44
Market Cap:
$6.22B
Revenue:
Net Income/Loss:
$-77.61M
P/E Ratio:
-67.19
EPS:
-2.2979
Net Cash Flow:
1W Performance:
+1.22%
1M Performance:
-8.89%
6M Performance:
-8.52%
1Y Performance:
+89.99%
1-Day Range:
$152.20
$155.47
1-Week Range:
$150.02
$161.00
52-Week Range:
$78.71
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
154.38 | 6.22B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
509.74 | 129.20B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.40 | 95.18B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.26 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.01 | 53.39B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-26 | Initiated | Canaccord Genuity | Buy |
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio CMO Scholl sells $82,658 in shares By Investing.com - Investing.com South Africa
Form 4 Belite Bio Inc ADR For: 5 October By Investing.com - Investing.com UK
Belite Bio CMO Scholl sells $82,658 in shares - Investing.com
4,000 Belite Bio (BLTE) depositary shares are proposed for sale, valued at $679K. - Stock Titan
Belite Bio (BLTE) Climbs 1.97% to $169.94 as Shares Hold Above Key SupportValue Area High - https://www.siam.in/
Belite Bio, IncAmerican Depositary Shares (Nasdaq:BLTE) Detailed Stock Data - The Chronicle-Journal
Belite Bio at Cantor healthcare conference: tinlarebant advances - Investing.com India
Belite Bio at Cantor healthcare conference: tinlarebant advances By Investing.com - Investing.com Canada
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs By Investing.com - Investing.com South Africa
Wednesday’s top insider buys and sells: NVIDIA leads activity By Investing.com - Investing.com Australia
Wednesday’s top insider buys and sells: NVIDIA leads activity By Investing.com - Investing.com India
Wednesday’s top insider buys and sells: NVIDIA leads activity - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com
Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com India
Belite Bio CFO Chuang Hao-Yuan sells $12.8 million in company ADSs - Investing.com Nigeria
Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - Investing.com Canada
Belite Bio CEO Lin Yu-Hsin sells $19.08m in company shares - Investing.com UK
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com Nigeria
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com Australia
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com Australia
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross - Zacks Investment Research
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - investing.com
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com UK
Belite Bio stock price target raised to $245 by H.C. Wainwright on Japan NDA filing - Investing.com
Mizuho raises Belite Bio stock price target on Japan drug filing - Investing.com
Mizuho raises Belite Bio stock price target on Japan drug filing By Investing.com - Investing.com South Africa
Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com Canada
Belite Bio at Wells Fargo conference: nda review lifts stakes By Investing.com - Investing.com UK
Belite Bio files Japan NDA for Stargardt disease drug - grafa.com
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com Nigeria
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com South Africa
Belite Bio Files Sakigake-Backed Tinlarebant NDA in Japan for Stargardt Disease - TipRanks
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt... - markets.businessinsider.com
Belite Bio submits drug application in Japan for Stargardt disease By Investing.com - Investing.com Canada
Belite Bio submits drug application in Japan for Stargardt disease - investing.com
Belite Bio (NASDAQ: BLTE) seeks Japan OK for Stargardt pill that could be a first - Stock Titan
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com South Africa
Belite Bio Pops As Wall Street Backs Stargardt Bet - TipRanks
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com Nigeria
Canaccord initiates Belite Bio stock with buy on Stargardt therapy - investing.com
Canaccord initiates Belite Bio stock with buy on Stargardt therapy By Investing.com - Investing.com UK
Belite Bio Surges As Tinlarebant Nears FDA Decision - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans - Investing.com
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com India
H.C. Wainwright reiterates Belite Bio stock rating on commercial plans By Investing.com - Investing.com Canada
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Belite Bio Inc Adr Stock (BLTE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hendrik Peter Scholl | Officer |
Oct 01 '26 |
Proposed Sale |
169.82 |
4,000 |
679,280 |
0 |
| Chuang Hao-Yuan | Chief Financial Officer |
Sep 08 '26 |
Sale |
196.42 |
17,962 |
3,528,139 |
26,038 |
| Lin Yu-Hsin | Chief Executive Officer |
Sep 08 '26 |
Sale |
196.56 |
26,000 |
5,110,486 |
70,134 |
| Lin Yu-Hsin | Chief Executive Officer |
Sep 04 '26 |
Sale |
187.71 |
74,435 |
13,972,063 |
96,134 |
| Chuang Hao-Yuan | Chief Financial Officer |
Sep 04 '26 |
Sale |
187.64 |
49,433 |
9,275,389 |
44,000 |
| Yu-Hsin Lin | CEO, Chairman |
Aug 12 '26 |
Proposed Sale |
177.58 |
126,800 |
22,517,144 |
0 |
| Hao-Yuan Chuang | Officer, Director |
Aug 12 '26 |
Proposed Sale |
177.58 |
93,800 |
16,657,004 |
0 |
| Chuang Hao-Yuan | Chief Financial Officer |
Aug 12 '26 |
Sale |
180.35 |
367 |
66,187 |
93,433 |
| Lin Yu-Hsin | Chief Executive Officer |
Aug 12 '26 |
Sale |
180.35 |
365 |
65,827 |
170,569 |
| Dr. Hendrick P. Scholl | Affiliate |
Jun 18 '26 |
Proposed Sale |
148.34 |
10,000 |
1,483,400 |
0 |
1.95%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):